Could stem cell islets end daily insulin shots?

NCT ID NCT05791201

Ongoing Disease control Sponsor: Vertex Pharmaceuticals Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests VX-264, a therapy made from stem cells that produce insulin, in 7 people with long-standing type 1 diabetes. The goal is to see if it is safe and can help control blood sugar. If successful, it may reduce or replace the need for insulin injections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stem cell-derived insulin-producing cells (VX-264)
What this could lead to: If it works, this could free people with type 1 diabetes from daily insulin injections by providing a renewable source of insulin-making cells.
What could go wrong: This is a very early, small trial (only 7 participants) focused on safety. The cells may not survive long-term, and participants may still need immunosuppressant drugs, which carry risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Locations

Churchill Hospital

Headington, United Kingdom
Dresden Center for Islet Transplantation

Dresden, Germany
Hopiteaux Universitaires de Geneve

Geneva, Switzerland
Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
IRCCS Ospedale San Raffaele

Milan, Italy
Leiden University

Leiden, Netherlands
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Montreal Clinical Research Institute

Montreal, Canada
Royal Victoria Infirmary

Newcastle upon Tyne, United Kingdom
Toronto General Hospital (TGH)

Toronto, Canada
UHealth Diabetes Research Institute

Miami, Florida, 33136, United States
University of Alberta, Edmonton

Edmonton, Canada
University of Chicago

Chicago, Illinois, 60637, United States
University of Pittsburgh Medical Center Montefiore

Pittsburgh, Pennsylvania, 15213, United States
University of Wisconsin

Madison, Wisconsin, 53792, United States
Vancouver General Hospital

Vancouver, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.